We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRedx Pharma Regulatory News (REDX)

Share Price Information for Redx Pharma (REDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 11.25
Bid: 10.50
Ask: 12.00
Change: 2.40 (26.67%)
Spread: 1.50 (14.286%)
Open: 9.00
High: 11.40
Low: 9.00
Prev. Close: 9.00
REDX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) Redx Pharma plc

17 Mar 2020 14:30

RNS Number : 4869G
Redx Pharma plc
17 March 2020
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Redx Pharma plc ("Redx")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Redx Pharma plc

(d) Is the discloser the offeror or the offeree?

OFFEROR / OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

17 March 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES / NO / N/A

If YES, specify which:

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

1p ordinary shares

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

n/a

n/a

(2) Cash-settled derivatives:

 

n/a

n/a

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

n/a

n/a

 

TOTAL:

n/a

n/a

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

n/a

Details, including nature of the rights concerned and relevant percentages:

n/a

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Interest of Redx Directors and connected advisers in Redx shares:

Name

Number of Shares

% of issued share capital

Iain Ross

600,000

0.32

Dr. Bernhard Kirschbaum

50,000

0.02

Peter Presland

120,000

0.06

WG Partners LLP

114,593

0.06

 

Interest of Redx Directors in options over Redx shares:

Name

No. of options

Exercise price

Vesting date

Expiry date

Lisa Anson

600,000

13.75p

4 June 2018

3 June 2028

Lisa Anson

600,000

20p

4 June 2018

3 June 2028

Lisa Anson

600,000

27p

4 June 2019

3 June 2028

Lisa Anson

600,000

35p

4 June 2019

3 June 2028

Lisa Anson

600,000

42.5p

4 June 2020

3 June 2028

Lisa Anson

600,000

50p

4 June 2020

3 June 2028

Dr. James Mead

200,000

13.75p

13 February 2019

12 February 2029

Dr. James Mead

200,000

20p

13 February 2019

12 February 2029

Dr. James Mead

200,000

27p

13 February 2020

12 February 2029

Dr. James Mead

200,000

35p

13 February 2020

12 February 2029

Dr. James Mead

200,000

42.5p

13 February 2021

12 February 2029

Dr. James Mead

200,000

50p

13 February 2021

12 February 2029

 

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

YES/NO

Supplemental Form 8 (SBL)

YES/NO

 

 

Date of disclosure:

17 March 2020

Contact name:

James Mead

Telephone number:

01625 496 609

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEEFLFLSVSIDLII
Date   Source Headline
29th Apr 20247:00 amRNSUpdate on AIM Delisting
22nd Apr 20245:45 pmRNSTR-1: Notification of major holdings
19th Apr 202412:18 pmRNSResult of GM, Cancellation of Admission to Trading
18th Apr 20247:00 amRNSShare Purchases by a Director
12th Apr 20247:00 amRNSShare Purchase by a Director
10th Apr 20247:00 amRNSUpdate on Broking Arrangements
8th Apr 20243:32 pmRNSTR-1: Notification of major holdings
2nd Apr 20247:00 amRNSProposed Cancellation of Admission to Trading
14th Mar 202411:27 amRNSResult of AGM
6th Mar 20247:00 amRNSRedx to Exhibit Three Posters at AACR
28th Feb 20247:00 amRNSFirst Participant Dosed in Phase 1 Trial of RXC008
26th Feb 20247:00 amRNSRedx to Present at Cowen Health Care Conference
23rd Feb 20247:00 amRNSNew Grant of Options
16th Feb 20244:50 pmRNSNotice of AGM
14th Feb 20247:00 amRNSStatement re Press Report
8th Feb 20241:02 pmRNSTR-1: Notification of major holdings
7th Feb 20247:00 amRNSRedx announces sale of KRAS inhibitor program
15th Dec 20237:00 amRNSFinal Audited Results for Year Ended 30 September
12th Dec 20237:00 amRNSNotice of Preliminary Results
9th Nov 20237:00 amRNSHoldings in Company
8th Nov 20231:58 pmRNSTR-1: Notification of major holdings
8th Nov 20231:55 pmRNSTR-1: Notification of major holdings
7th Nov 20238:10 amRNSAdmission of Subscription Shares and TVR
6th Nov 202311:22 amRNSResults of General Meeting
6th Nov 20237:00 amRNSRedx Unveils Preclinical Data from RXC009
30th Oct 20237:00 amRNSRedx to present preclinical data on RXC009 at ASN
18th Oct 20237:00 amRNSProposed Subscription to raise c.£14.1 million
22nd Aug 20237:00 amRNSDirectorate Change
21st Aug 20237:00 amRNSZelasudil granted FDA Orphan Drug Designation
10th Jul 20237:00 amRNSExtension to Termination of Convertible Loan Notes
3rd Jul 20237:00 amRNSDirectorate Change
30th Jun 20237:00 amRNSNew Grant of Options
31st May 20237:00 amRNSRedx to present at Jefferies Healthcare Conference
17th May 20237:00 amRNSInterim Results for the Six Months Ended 31 March
12th May 20239:51 amRNSDiscovery of Pirtobrutinib Recognised with Plaque
11th May 20237:00 amRNSPresentation of RXC007 Preclinical Efficacy Data
10th May 20237:00 amRNSNotice of Interim Results
3rd May 20237:00 amRNSRedx to Present at Keystone Symposia
3rd Apr 20237:01 amRNSProposed Business Combination Formally Lapsed
3rd Apr 20237:00 amRNSTermination of Proposed Business Combination
30th Mar 20238:36 amRNSForm 8.5 (EPT/RI) - Redx Pharma plc
27th Mar 20232:06 pmRNSStatement Following Jounce Announcement
27th Mar 20232:00 pmRNSStatement re Merger Agreement
24th Mar 20232:31 pmRNSForm 8.3 - Jounce Therapeutics, Inc
22nd Mar 20232:20 pmRNSForm 8.3 - Jounce Therapeutics, Inc
20th Mar 20233:00 pmRNSForm 8.3 - Jounce Therapeutics, Inc
20th Mar 202310:38 amRNSForm 8.5 (EPT/RI)
16th Mar 20239:48 amRNSForm 8.5 (EPT/RI)
15th Mar 20234:40 pmRNSSecond Price Monitoring Extn
15th Mar 20234:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.